Risk of skin rash associated with erlotinib in cancer patients: A meta-analysis

Yuxia Jia, Mario E. Lacouture, Xiao Su, Shenhong Wu

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Skin rash is a major side effect of erlotinib, an inhibitor of the epidermal growth factor receptor widely used in cancer treatment and clinical trials. This study aims to evaluate the risk of skin toxicity with erlotinib through a systematic review and meta-analysis of randomized controlled clinical trials (RCTs). Eligible studies included prospective RCTs in which erlotinib was compared with controls at the starting dose of 150 mg daily. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated using a random-effects or fixed-effects model based on the heterogeneity of included studies. A total of 2,911 patients with a variety of solid tumors from 9 RCTs were included for analysis. The overall incidence of all-grade skin rash associated with erlotinib was 70.4% (95% CI: 67.2%-73.4%), with 9.4% (95% CI: 8.0%-11.0%) being high grade (grade 3 or above). There was a significantly increased risk of all-grade rash with erlotinib in comparison with controls (RR, 3.43; 95% CI: 2.13-5.52; P < 0.001). The incidence of all-grade rash was significantly lower in patients treated with the combination of erlotinib and chemotherapy than with erlotinib alone (risk ratio, 0.84; 95% CI, 0.77-0.93; P = 0.001). In addition, RR of all-grade rash was 4.72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalJournal of Supportive Oncology
Volume7
Issue number6
StatePublished - Dec 1 2009

Fingerprint

Exanthema
Meta-Analysis
Confidence Intervals
Neoplasms
Randomized Controlled Trials
Incidence
Erlotinib Hydrochloride
Skin
Combination Drug Therapy
Epidermal Growth Factor Receptor
Odds Ratio
Clinical Trials
Prospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Jia, Yuxia ; Lacouture, Mario E. ; Su, Xiao ; Wu, Shenhong. / Risk of skin rash associated with erlotinib in cancer patients : A meta-analysis. In: Journal of Supportive Oncology. 2009 ; Vol. 7, No. 6. pp. 211-217.
@article{25af98df770f42d4be11e11feecf8e85,
title = "Risk of skin rash associated with erlotinib in cancer patients: A meta-analysis",
abstract = "Skin rash is a major side effect of erlotinib, an inhibitor of the epidermal growth factor receptor widely used in cancer treatment and clinical trials. This study aims to evaluate the risk of skin toxicity with erlotinib through a systematic review and meta-analysis of randomized controlled clinical trials (RCTs). Eligible studies included prospective RCTs in which erlotinib was compared with controls at the starting dose of 150 mg daily. Incidence, relative risk (RR), and 95{\%} confidence intervals (CIs) were calculated using a random-effects or fixed-effects model based on the heterogeneity of included studies. A total of 2,911 patients with a variety of solid tumors from 9 RCTs were included for analysis. The overall incidence of all-grade skin rash associated with erlotinib was 70.4{\%} (95{\%} CI: 67.2{\%}-73.4{\%}), with 9.4{\%} (95{\%} CI: 8.0{\%}-11.0{\%}) being high grade (grade 3 or above). There was a significantly increased risk of all-grade rash with erlotinib in comparison with controls (RR, 3.43; 95{\%} CI: 2.13-5.52; P < 0.001). The incidence of all-grade rash was significantly lower in patients treated with the combination of erlotinib and chemotherapy than with erlotinib alone (risk ratio, 0.84; 95{\%} CI, 0.77-0.93; P = 0.001). In addition, RR of all-grade rash was 4.72 (95{\%} CI: 3.56-6.20) for erlotinib alone and 2.34 (95{\%} CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy.",
author = "Yuxia Jia and Lacouture, {Mario E.} and Xiao Su and Shenhong Wu",
year = "2009",
month = "12",
day = "1",
language = "English (US)",
volume = "7",
pages = "211--217",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "6",

}

Jia, Y, Lacouture, ME, Su, X & Wu, S 2009, 'Risk of skin rash associated with erlotinib in cancer patients: A meta-analysis', Journal of Supportive Oncology, vol. 7, no. 6, pp. 211-217.

Risk of skin rash associated with erlotinib in cancer patients : A meta-analysis. / Jia, Yuxia; Lacouture, Mario E.; Su, Xiao; Wu, Shenhong.

In: Journal of Supportive Oncology, Vol. 7, No. 6, 01.12.2009, p. 211-217.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Risk of skin rash associated with erlotinib in cancer patients

T2 - A meta-analysis

AU - Jia, Yuxia

AU - Lacouture, Mario E.

AU - Su, Xiao

AU - Wu, Shenhong

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Skin rash is a major side effect of erlotinib, an inhibitor of the epidermal growth factor receptor widely used in cancer treatment and clinical trials. This study aims to evaluate the risk of skin toxicity with erlotinib through a systematic review and meta-analysis of randomized controlled clinical trials (RCTs). Eligible studies included prospective RCTs in which erlotinib was compared with controls at the starting dose of 150 mg daily. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated using a random-effects or fixed-effects model based on the heterogeneity of included studies. A total of 2,911 patients with a variety of solid tumors from 9 RCTs were included for analysis. The overall incidence of all-grade skin rash associated with erlotinib was 70.4% (95% CI: 67.2%-73.4%), with 9.4% (95% CI: 8.0%-11.0%) being high grade (grade 3 or above). There was a significantly increased risk of all-grade rash with erlotinib in comparison with controls (RR, 3.43; 95% CI: 2.13-5.52; P < 0.001). The incidence of all-grade rash was significantly lower in patients treated with the combination of erlotinib and chemotherapy than with erlotinib alone (risk ratio, 0.84; 95% CI, 0.77-0.93; P = 0.001). In addition, RR of all-grade rash was 4.72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy.

AB - Skin rash is a major side effect of erlotinib, an inhibitor of the epidermal growth factor receptor widely used in cancer treatment and clinical trials. This study aims to evaluate the risk of skin toxicity with erlotinib through a systematic review and meta-analysis of randomized controlled clinical trials (RCTs). Eligible studies included prospective RCTs in which erlotinib was compared with controls at the starting dose of 150 mg daily. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated using a random-effects or fixed-effects model based on the heterogeneity of included studies. A total of 2,911 patients with a variety of solid tumors from 9 RCTs were included for analysis. The overall incidence of all-grade skin rash associated with erlotinib was 70.4% (95% CI: 67.2%-73.4%), with 9.4% (95% CI: 8.0%-11.0%) being high grade (grade 3 or above). There was a significantly increased risk of all-grade rash with erlotinib in comparison with controls (RR, 3.43; 95% CI: 2.13-5.52; P < 0.001). The incidence of all-grade rash was significantly lower in patients treated with the combination of erlotinib and chemotherapy than with erlotinib alone (risk ratio, 0.84; 95% CI, 0.77-0.93; P = 0.001). In addition, RR of all-grade rash was 4.72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=73449114610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449114610&partnerID=8YFLogxK

M3 - Review article

C2 - 20380328

AN - SCOPUS:73449114610

VL - 7

SP - 211

EP - 217

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 6

ER -